ALPHARETTA, Ga.–(BUSINESS WIRE)– #nationalvision–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will report its second quarter 2026 financial results before the market opens on Wednesday, August 12, 2026, and will …
Author: Business Wire
Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2026 financial results. “Broad-based revenue gr…
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the c…
Northwell Scientist Reveals Breakthrough Results in Eye Cancer Drug
MANHASSET, N.Y.–(BUSINESS WIRE)–Patients with metastatic uveal melanoma (UM), an aggressive eye cancer, often face a survival rate of less than two years once the disease spreads. While established treatment options are limited, to help patients livi…
Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results
INCHEON, Korea–(BUSINESS WIRE)– #biosimilars–Samsung Epis Holdings announced its financial results for the second quarter and first half of fiscal year 2026.
iVeena Delivery Systems Announces Positive End-of-Phase 1 FDA Meeting for IVMED-85
SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems, Inc., “iVeena” a clinical-stage ophthalmic pharmaceutical company developing innovative therapies for eye diseases, today announced a successful End-of-Phase 1 Type B meeting with the U.S. Food …
Science Corp. Announces European Commercial Launch of PRIMA, the Only Treatment to Restore Functional Central Vision to Patients with Geographic Atrophy Caused by Age-Related Macular Degeneration, a Leading Cause of Blindness
ALAMEDA, Calif. & PARIS–(BUSINESS WIRE)–Science Corporation, the neural engineering and brain-computer interface (BCI) company, today announced the European commercial launch of PRIMA, the first and only treatment shown in clinical trials to restore …
レストアビジョンとForge Biologics、アデノ随伴ウイルス（AAV）開発およびcGMP製造におけるパートナーシップを発表
東京＆米オハイオ州コロンバス–(BUSINESS WIRE)–（ビジネスワイヤ） — 網膜疾患に対する遺伝子治療薬の開発を進める臨床段階のバイオテクノロジー企業である株式会社レストアビジョン（「レストアビジョン」）と、遺伝子治療薬の大手メーカーで味の素バイオファーマサービスグループの一部であるForge Biologics（「Forge」）は、レストアビジョンが開発中の網膜色素変性症患者向けGPCRベースの光遺伝学的AAV遺伝子治療薬RV-001を支援するための開発・製造パートナーシップを発表…
Restore Vision and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership
TOKYO & COLUMBUS, Ohio–(BUSINESS WIRE)–Restore Vision, Inc. (“Restore Vision”), a clinical-stage biotechnology company advancing gene therapies for retinal disorders, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member …
Radiology Partners Strengthens RP Clinical Services Leadership with Matt Peterson as President and Krishna Nallamshetty, MD, as Chief Operating Officer
NASHVILLE, Tenn.–(BUSINESS WIRE)–Radiology Partners, Inc. (RP), through RP Clinical Services and its affiliated practices, today announced two leadership appointments, effective July 20. Matt Peterson has been named President of RP Clinical Services,…
Inflammasome Therapeutics Reports Positive Six-Month Phase 2 Results for K8 in Geographic Atrophy
NEWTON, Mass.–(BUSINESS WIRE)–Inflammasome Therapeutics’ K8 slowed GA lesion growth 54% and showed a 4.0-letter vision advantage at six months in Phase 2. Phase 3 planned.
iVeena Delivery Systems Announces Successful Completion of Phase 1 Clinical Study of IVMED-85
SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems, Inc., (“iVeena”) a clinical-stage ophthalmic biopharmaceutical company, today announced the successful completion of its Phase 1 clinical trial evaluating the safety of IVMED-85, an investigatio…
STAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the se…
Riassunto: Compvide™ annuncia una collaborazione strategica con OpZira™ per velocizzare la crescita e lo sviluppo della piattaforma CIMED™
SEATTLE–(BUSINESS WIRE)–Compvide, Inc., il pioniere biotech dell’intelligence dei complementi funzionali tramite la diagnostica innovativa e il monitoraggio della risposta immunitaria, oggi ha dato il via a una collaborazione strategica con OpZira, I…
Compvide™ annonce un partenariat stratégique avec OpZira™ pour accélérer sa croissance et renforcer la plateforme CIMED™
SEATTLE–(BUSINESS WIRE)–Compvide, Inc., société de biotechnologie pionnière dans le domaine de l’intelligence fonctionnelle du système du complément grâce à des outils diagnostiques innovants et au suivi de la réponse immunitaire, a annoncé aujourd’h…
Compvide™ gibt strategische Zusammenarbeit mit OpZira™ bekannt zwecks Wachstum und Förderung der CIMED™ -Plattform
SEATTLE–(BUSINESS WIRE)–Compvide Inc., ein Biotechnologieunternehmen, das durch innovative Diagnostik und die Überwachung von Immunreaktionen Pionierarbeit im Bereich der funktionellen Komplement-Intelligenz leistet, gab heute eine strategische Zusam…
Samenvatting: Compvide™ kondigt strategische samenwerking met OpZira™ aan om de groei te versnellen en het CIMED™-platform verder te ontwikkelen
SEATTLE–(BUSINESS WIRE)–Compvide, Inc., een biotechnologiebedrijf dat baanbrekend werk verricht op het gebied van functionele complementintelligentie door middel van innovatieve diagnostiek en monitoring van immuunreacties, heeft vandaag een strategi…
Resumen: Compvide™ anuncia una colaboración estratégica con OpZira™ para acelerar el crecimiento y desarrollar la plataforma CIMED™
SEATTLE–(BUSINESS WIRE)–Compvide, Inc., una empresa de biotecnología pionera en el campo de la inteligencia del complemento funcional mediante diagnósticos innovadores y la monitorización de la respuesta inmunitaria, ha anunciado hoy una colaboración…
Warby Parker to Announce Second Quarter 2026 Financial Results on August 6, 2026
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the second quarter ended June 30, 2026, will be released before ma…
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery …